JP2017511807A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511807A5
JP2017511807A5 JP2016560040A JP2016560040A JP2017511807A5 JP 2017511807 A5 JP2017511807 A5 JP 2017511807A5 JP 2016560040 A JP2016560040 A JP 2016560040A JP 2016560040 A JP2016560040 A JP 2016560040A JP 2017511807 A5 JP2017511807 A5 JP 2017511807A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560040A
Other versions
JP6590830B2 (ja
JP2017511807A (ja
Filing date
Publication date
Priority claimed from EP13199325.5A external-priority patent/EP2886126B1/en
Application filed filed Critical
Publication of JP2017511807A publication Critical patent/JP2017511807A/ja
Publication of JP2017511807A5 publication Critical patent/JP2017511807A5/ja
Application granted granted Critical
Publication of JP6590830B2 publication Critical patent/JP6590830B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560040A 2013-12-23 2014-12-22 Ｃｄ４４結合ペプチド Expired - Fee Related JP6590830B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13199325.5A EP2886126B1 (en) 2013-12-23 2013-12-23 Nanoparticle conjugated to CD44 binding peptides
EP13199325.5 2013-12-23
PCT/EP2014/079028 WO2015097170A1 (en) 2013-12-23 2014-12-22 Cd44 binding peptides

Publications (3)

Publication Number Publication Date
JP2017511807A JP2017511807A (ja) 2017-04-27
JP2017511807A5 true JP2017511807A5 (ja) 2017-07-13
JP6590830B2 JP6590830B2 (ja) 2019-10-23

Family

ID=49885052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560040A Expired - Fee Related JP6590830B2 (ja) 2013-12-23 2014-12-22 Ｃｄ４４結合ペプチド

Country Status (14)

Country Link
US (2) US20170073392A1 (ja)
EP (2) EP2886126B1 (ja)
JP (1) JP6590830B2 (ja)
KR (1) KR20160102057A (ja)
CN (1) CN106061496A (ja)
AU (1) AU2014372600B2 (ja)
CA (1) CA2933305C (ja)
DK (2) DK2886126T3 (ja)
ES (2) ES2639855T3 (ja)
PL (2) PL2886126T3 (ja)
PT (2) PT2886126T (ja)
RU (1) RU2016126425A (ja)
SG (1) SG11201604663SA (ja)
WO (1) WO2015097170A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2886126T3 (en) * 2013-12-23 2017-09-18 Exchange Imaging Tech Gmbh Nanoparticle conjugated to CD44-binding peptides
CN107033216B (zh) * 2015-12-08 2021-08-03 财团法人农业科技研究院 靶向癌干细胞的胜肽和其应用
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
EP3720506A4 (en) * 2017-12-04 2021-09-29 Lecouteur, David COMPOSITIONS AND METHODS FOR MODULATING THE WINDOWS OF HEPATIC ENDOTHELIAL CELLS
KR102082224B1 (ko) 2018-04-09 2020-02-26 이치영 계단실을 통한 화재확산을 방지하기 위한 방화 구조 및 화재확산 방지 방법
US20230079732A1 (en) * 2020-01-17 2023-03-16 The University Of Sydney Opal peptide administration
JP2023526529A (ja) 2020-05-19 2023-06-21 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
JP7335520B2 (ja) * 2021-06-21 2023-08-30 日亜化学工業株式会社 波長変換部材、発光装置及び画像表示装置
EP4430059A1 (en) * 2021-11-12 2024-09-18 The Regents of The University of Michigan Cd44-binding peptide reagents and methods
CN114891742B (zh) * 2022-06-23 2024-06-04 杭州中赢生物医疗科技有限公司 一种强杀伤性nk细胞的培养基及体外扩增方法
CN116496398B (zh) * 2022-10-31 2023-10-31 南京元迈细胞生物科技有限公司 一种特异性结合CD44的v5外显子的抗体及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DE4014510A1 (de) 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE4134982A1 (de) 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression
JPH08511624A (ja) 1993-06-22 1996-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍の診断方法及び分析方法
DE4326573A1 (de) 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
US6179912B1 (en) 1999-12-20 2001-01-30 Biocrystal Ltd. Continuous flow process for production of semiconductor nanocrystals
AU2001233114A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
DE10016559A1 (de) 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7205048B2 (en) 2001-09-17 2007-04-17 Invitrogen Corporation Functionalized fluorescent nanocrystal compositions and methods of making
EP1440458B1 (en) 2001-10-02 2007-01-10 Invitrogen Corporation Method of semiconductor nanoparticle synthesis
US20070269895A1 (en) * 2002-06-03 2007-11-22 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
CN1672052A (zh) 2002-06-27 2005-09-21 佐治亚技术研究公司 纳米级光学荧光标记及其用途
DE10245508A1 (de) 2002-09-27 2004-04-08 Mcs Micro Carrier Systems Gmbh Medikament-Dosimeter-Kombipackung
WO2004072277A2 (en) * 2003-02-13 2004-08-26 Asahi Kasei Pharma Corporation Elk1 phosphorylation related genes
WO2005001889A2 (en) 2003-05-07 2005-01-06 Indiana University Research & Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
EP1646657B1 (en) * 2003-07-15 2011-11-16 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antibodies to cd44 vra and methods of use
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
DE102004032781A1 (de) 2004-01-23 2005-08-11 Mcs Micro Carrier Systems Gmbh Bisphosphonsäurederivate
US7482059B2 (en) 2004-05-10 2009-01-27 Evident Technologies Semiconductor nanocrystal complexes comprising a metal coating and methods of making same
US20070045777A1 (en) 2004-07-08 2007-03-01 Jennifer Gillies Micronized semiconductor nanocrystal complexes and methods of making and using same
ATE411384T1 (de) 2005-05-04 2008-10-15 Signalomics Gmbh Kompetitives n-hybrid system
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
GB2429838B (en) 2005-08-12 2011-03-09 Nanoco Technologies Ltd Nanoparticles
US7582441B1 (en) * 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease
ES2627998T3 (es) 2005-11-16 2017-08-01 Exchange Imaging Technologies Gmbh Nanopartículas fluorescentes
US20080286826A1 (en) 2005-11-22 2008-11-20 Koninklijke Philips Electronics, N.V. Luminescent Particle and Method of Detecting a Biological Entity Using a Luminescent Particle
US20080038558A1 (en) 2006-04-05 2008-02-14 Evident Technologies, Inc. I-iii-vi semiconductor nanocrystals, i-iii-vi water stable semiconductor nanocrystals, and methods of making same
US20080012001A1 (en) 2006-07-12 2008-01-17 Evident Technologies Shaped articles comprising semiconductor nanocrystals and methods of making and using same
US8409473B2 (en) 2007-01-30 2013-04-02 Evident Technologies, Inc. Group II alloyed I-III-VI semiconductor nanocrystal compositions and methods of making same
US8168586B1 (en) * 2007-11-21 2012-05-01 Celera Corporation Cancer targets and uses thereof
JP5552437B2 (ja) 2008-02-29 2014-07-16 シグナロミクス ゲーエムベーハー 最適化されたアドへシンフラグメントおよび対応するナノ粒子
GB0813273D0 (en) 2008-07-19 2008-08-27 Nanoco Technologies Ltd Method for producing aqueous compatible nanoparticles
GB0814458D0 (en) 2008-08-07 2008-09-10 Nanoco Technologies Ltd Surface functionalised nanoparticles
GB0820101D0 (en) 2008-11-04 2008-12-10 Nanoco Technologies Ltd Surface functionalised nanoparticles
WO2010058396A1 (en) * 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
KR102184715B1 (ko) 2011-12-22 2020-11-30 나노코 테크놀로지스 리미티드 표면 변형된 나노입자들
DK2886126T3 (en) * 2013-12-23 2017-09-18 Exchange Imaging Tech Gmbh Nanoparticle conjugated to CD44-binding peptides

Similar Documents

Publication Publication Date Title
RU2017110477A3 (ja)
BR112016027525A2 (ja)
BR112016016756A2 (ja)
BR112016018633A2 (ja)
BR112016027506A2 (ja)
BR112016018868A2 (ja)
BR112016017201A2 (ja)
BR112016016978A2 (ja)
BR112016016546A2 (ja)
BR112016026300A2 (ja)
BR112016026807A2 (ja)
BR112016016689A2 (ja)
BR112016021197A2 (ja)
BR112016023487A2 (ja)
BR112016017226A2 (ja)
BR112016019099A2 (ja)
BR112015033030A2 (ja)
BR112016027088A2 (ja)
BR112016022869A2 (ja)
BR112016018965A2 (ja)
BR112016018830A2 (ja)
JP2017511807A5 (ja)
BR112016017538A2 (ja)
BR112016026370A2 (ja)
BR112016019543A2 (ja)